check_circleStudy Completed

Contraception

Acceptability of long-term progestin-only contraception in Europe

Trial purpose

The study examines the use of Mirena or Implanon for long-term contraception in women. The duration of therapy use is the key focus of the study. Also, any reasons for discontinuation and the safety profile will be examined. In addition, patients are asked to fill out a short questionnaire about their menstrual bleeding before and during therapy.

Key Participants Requirements

Sex

Female

Age

20 - 35 Years

Trial summary

Enrollment Goal
436
Trial Dates
January 2008 - November 2011
Phase
N/A
Could I Receive a placebo
No
Products
Mirena (Levonorgestrel IUS, BAY86-5028)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Many Locations, United Kingdom
Completed
Many Locations, France
Completed
Many Locations, Slovakia
Completed
Many Locations, Ireland

Primary Outcome

  • Continuation rate
    date_rangeTime Frame:
    At 24 months
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Continuation rate
    date_rangeTime Frame:
    At 12 months
    enhanced_encryption
    Safety Issue:
    No
  • Bleeding intensity, dysmenorrhea, and user satisfaction (questionnaires completed by patient)
    date_rangeTime Frame:
    Initial and after 3, 6, 12 and 24 months
    enhanced_encryption
    Safety Issue:
    No
  • Cumulative discontinuation rate for unintended pregnancy, bleeding problems, other medical reasons, for non-medical reasons
    date_rangeTime Frame:
    At 24 months
    enhanced_encryption
    Safety Issue:
    No
  • Incidence of Adverse Events, Serious Adverse Events
    date_rangeTime Frame:
    During 24 months
    enhanced_encryption
    Safety Issue:
    Yes
  • The return to fertility of women discontinuing the method for wish for pregnancy
    date_rangeTime Frame:
    12 months after discontinuation
    enhanced_encryption
    Safety Issue:
    No

Trial design

Acceptability of long-term progestin-only contraception in Europe
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A